市場調査レポート

商品コード

1458418

創傷治療用バイオロジクス市場の評価：製品・創傷・エンドユーザー・地域別の機会および予測 (2017-2031年)

Wound Care Biologics Market Assessment, By Product, By Wound, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年04月01日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 225 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の創傷治療用バイオロジクスの市場規模は、2023年の20億1,000万米ドルから、2024年から2031年の予測期間中は6.45%のCAGRで推移し、2031年には33億1,000万米ドルの規模に成長すると予測されています。

糖尿病性足潰瘍と熱傷の増加：

同市場の成長は、熱傷と糖尿病性足潰瘍の罹患率の上昇が大きな要因となっています。糖尿病性足潰瘍は、糖尿病の有病率が世界的に上昇する中で一般的になりつつある合併症のひとつです。毎年、米国では160万人、世界では1,860万人が糖尿病性足潰瘍に苦しんでいます。糖尿病患者の約1％が足を切断し、患者の5％が足潰瘍を発症しています。ここ数年、糖尿病患者の1～4％が毎年足潰瘍を発症していると推定されています。火傷は、世界全体で毎年18万人の死亡原因となっているため、公衆衛生上の懸念事項です。そのほぼ3分の2がアフリカと中東アジア地域で発生しており、大部分は中低所得国で発生しています。創傷治療用バイオロジクスの一部である皮膚代替物や成長因子などの先進的な治療法は、治癒を促進し、合併症を減らす効果があることから、ますます人気が高まっています。このような意識の高まりと、革新的で効率的な創傷ケアソリューションに対するニーズの高まりの結果、創傷治療用バイオロジクスは熱傷や糖尿病性足潰瘍に関連する問題の解決に不可欠なものと位置づけられています。

交通事故の増加：

世界の交通事故率は上昇しており、これが同市場の成長を促進する主な要因の1つとなっています。創傷治療用バイオロジクスの需要を牽引しているのは、迅速かつ効率的な創傷治癒に対するニーズの高まりと、生物学的製剤に基づく治療の臨床的利点に対する理解の深まりです。成長因子や組織工学製品などの先端療法は、治癒プロセスを促進し、外傷後の合併症の可能性を減らすために不可欠です。毎年、推定119万人が交通事故によって命を落としています。5歳から29歳の子供と若年成人層においては、交通事故は主な死因です。低・中所得国が世界の交通事故死者数の92％を占めています。

技術の進歩：

創傷治療用バイオロジクスの技術的進歩は、創傷治療の展望を大きく変えつつあります。革新的なアプローチでは、成長因子、幹細胞、サイトカインを利用して組織の再生を促し、治癒プロセスを加速します。組織工学と3Dプリンティング技術を活用した生物学的皮膚代替物は、従来の移植片に代わる優れた代替物を提供し、適合性と機能性を向上させています。局所剤はナノテクノロジーと徐放性製剤の恩恵を受けており、感染制御と創傷治癒における有効性が向上しています。

北米が世界の創傷治療用バイオロジクス市場を独占：

創傷治療用バイオロジクスの世界市場における北米の優位性は、さまざまな要因によるものです。同地域は、先進医療技術を容易に導入・統合できる医療インフラが確立されています。加えて、糖尿病や血管疾患などの慢性疾患の有病率が高いことから、高度な創傷ケアソリューションに対する需要が高まっており、生物製剤は治療プロトコルの重要な要素となっています。米国とカナダの規制環境と償還政策は、革新的な創傷治療用バイオロジクスの普及をさらに促進しています。

当レポートでは、世界の創傷治療用バイオロジクスの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
製品別
- 生物学的皮膚代替物
- 局所剤
創傷別
- 潰瘍
- 外科的創傷および外傷
- 熱傷
エンドユーザー別
- 病院・クリニック
- 外来手術センター
- 熱傷治療センター・創傷クリニック
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界の創傷治療用バイオロジクス市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

製品別
創傷別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸入輸出分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因 (課題と抑制)

第9章規制の枠組みとイノベーション

特許情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析（参入5社）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の展望

Smith & Nephew Plc
Integra LifeSciences Corporation
Stryker Corporation
Organogenesis Inc
MixMedx Inc
Kerecis Limited
Molnlycke Healthcare AB
Lynch Biologics
Skye Biologics Holdings LLC
Marine Polymer Technologies Inc

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 2.Global Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 3.Global Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 4.Global Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 5.Global Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 6.Global Wound Care Biologics Market Share (%), By Region, 2017-2031F
Figure 7.North America Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 8.North America Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 9.North America Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 10.North America Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 11.North America Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 12.North America Wound Care Biologics Market Share (%), By Country, 2017-2031F
Figure 13.United States Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 14.United States Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 15.United States Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 16.United States Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 17.United States Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 18.Canada Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 19.Canada Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 20.Canada Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 21.Canada Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 22.Canada Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 23.Mexico Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 24.Mexico Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 25.Mexico Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 26.Mexico Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 27.Mexico Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 28.Europe Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 29.Europe Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 30.Europe Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 31.Europe Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 32.Europe Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 33.Europe Wound Care Biologics Market Share (%), By Country, 2017-2031F
Figure 34.Germany Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 35.Germany Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 36.Germany Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 37.Germany Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 38.Germany Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 39.France Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 40.France Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 41.France Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 42.France Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 43.France Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 44.Italy Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 45.Italy Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 46.Italy Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 47.Italy Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 48.Italy Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 49.United Kingdom Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 50.United Kingdom Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 51.United Kingdom Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 52.United Kingdom Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 53.United Kingdom Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 54.Russia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 55.Russia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 56.Russia Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 57.Russia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 58.Russia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 59.Netherlands Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 60.Netherlands Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 61.Netherlands Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 62.Netherlands Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 63.Netherlands Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 64.Spain Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 65.Spain Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 66.Spain Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 67.Spain Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 68.Spain Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 69.Turkey Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 70.Turkey Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 71.Turkey Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 72.Turkey Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 73.Turkey Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 74.Poland Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 75.Poland Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 76.Poland Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 77.Poland Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 78.Poland Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 79.South America Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 80.South America Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 81.South America Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 82.South America Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 83.South America Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 84.South America Wound Care Biologics Market Share (%), By Country, 2017-2031F
Figure 85.Brazil Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 86.Brazil Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 87.Brazil Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 88.Brazil Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 89.Brazil Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 90.Argentina Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 91.Argentina Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 92.Argentina Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 93.Argentina Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 94.Argentina Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 95.Asia-Pacific Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 96.Asia-Pacific Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 97.Asia-Pacific Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 98.Asia-Pacific Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 99.Asia-Pacific Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 100.Asia-Pacific Wound Care Biologics Market Share (%), By Country, 2017-2031F
Figure 101.India Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 102.India Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 103.India Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 104.India Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 105.India Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 106.China Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 107.China Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 108.China Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 109.China Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 110.China Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 111.Japan Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 112.Japan Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 113.Japan Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 114.Japan Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 115.Japan Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 116.Australia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 117.Australia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 118.Australia Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 119.Australia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 120.Australia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 121.Vietnam Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 122.Vietnam Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 123.Vietnam Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 124.Vietnam Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 125.Vietnam Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 126.South Korea Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 127.South Korea Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 128.South Korea Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 129.South Korea Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 130.South Korea Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 131.Indonesia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 132.Indonesia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 133.Indonesia Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 134.Indonesia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 135.Indonesia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 136.Philippines Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 137.Philippines Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 138.Philippines Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 139.Philippines Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 140.Philippines Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 141.Middle East & Africa Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 142.Middle East & Africa Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 143.Middle East & Africa Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 144.Middle East & Africa Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 145.Middle East & Africa Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 146.Middle East & Africa Wound Care Biologics Market Share (%), By Country, 2017-2031F
Figure 147.Saudi Arabia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 148.Saudi Arabia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 149.Saudi Arabia Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 150.Saudi Arabia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 151.Saudi Arabia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 152.UAE Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 153.UAE Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 154.UAE Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 155.UAE Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 156.UAE Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 157.South Africa Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
Figure 158.South Africa Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
Figure 159.South Africa Wound Care Biologics Market Share (%), By Product, 2017-2031F
Figure 160.South Africa Wound Care Biologics Market Share (%), By Wound, 2017-2031F
Figure 161.South Africa Wound Care Biologics Market Share (%), By End-user, 2017-2031F
Figure 162.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163.By Wound Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11215

The global wound care biologics market is projected to witness a CAGR of 6.45% during the forecast period 2017-2031, growing from USD 2.01 billion in 2023 to USD 3.31 billion in 2031F. The global wound care biologics market consists of innovative treatments derived from natural sources or synthetic materials that are utilized in wound care procedures. These biologics include skin replacement products and stem cell therapies, which are essential for promoting tissue regeneration and wound healing. Bioengineered dermal substitutes and other biologic skin substitutes promote neovascularization and collagen formation, among other mechanisms that aid in the healing of chronic ulcers. To treat chronic wounds or diabetic foot ulcers with past histories and increased bioburden, topical agents derived from living organisms or cells are being used more often. Since biologic scaffolds form hydrogels that promote collagen synthesis and wound healing, their use in treating chronic non-healing wounds has shown effective results.

Wound care biologics are widely used in the management and treatment of burns, traumatic injuries, and foot ulcers. Anti-infective wound care products have demonstrated effectiveness in treating wounds with infection, such as diabetic foot ulcers. For long-standing foot ulcers or chronic wounds, biologic interventions have been clinically effective. The global wound care biologics market is being driven significantly by the increasing prevalence of burn injuries, traumatic wounds, and foot ulcers. Other factors that are driving the market growth are technological advancements, a growing geriatric population, and an increasing number of road accidents.

For instance, Biologics company Tides Medical announced the launch of a new product in July 2022, Artacent AC, a tri-layer skin graft designed for use in the treatment of complex or difficult-to-treat wounds. Artacent AC is three times stronger and two times thicker than traditional dual-layer products, making it easier to handle and apply to wound sites. To provide physicians with an advanced amniotic skin graft option, Tides developed Artacent AC, which consists of three layers (amnion-chorion-amnion) as opposed to the conventional two (amnion-amnion).

Increasing Prevalence of Diabetic Foot Ulcer and Burn Injuries

The global wound care biologics market is being driven largely due to the rising incidence of burn injuries and diabetic foot ulcers. Diabetic foot ulcers are among the associated complications that are becoming more common as the prevalence of diabetes increases globally. Every year, 1.6 million Americans and 18.6 million people worldwide suffer from diabetic foot ulcers. About 1% of diabetic patients have their feet amputated, and 5% of patients develop foot ulcers. Over the past few years, it has been estimated that 1-4% of diabetic patients develop foot ulcers each year. Burns are a public health concern since they are responsible for 180,000 deaths globally each year. Almost two-thirds of these are found in the African and South-East Asian regions, with the majority occurring in low- and middle-income countries. Advanced therapies such as skin substitutes and growth factors, which are a part of wound care biologics, are becoming more and more popular for their ability to boost healing and reduce complications. As a result of this increased awareness and the growing need for innovative and efficient wound care solutions, the market for wound care biologics has been positioned as essential to solving the problems associated with burn injuries and diabetic foot ulcers.

Growing Number of Road Accidents

Global traffic accident rates are rising, which is one of the key factors propelling the global wound care biologics market growth. Road accidents frequently cause a range of injuries, from small cuts to severe wounds, necessitating the use of cutting-edge wound care techniques. Demand for wound care biologics is being driven by the growing need for quick and efficient wound healing as well as a greater understanding of the clinical benefits of biologic-based treatments. Advanced therapies, such as growth factors and tissue-engineered products, are essential for accelerating the healing process and reducing the likelihood of complications following traumatic injuries. An estimated 1.19 million people lose their lives in traffic-related incidents each year. For kids and young adults aged 5 to 29, traffic accidents are the main cause of death. Despite having about 60% of the world's vehicles, low- and middle-income countries account for 92% of all road fatalities worldwide.

Technological Advancements

Technological advancements in the global wound care biologics market are revolutionizing the landscape of wound care management. Innovative approaches involve the utilization of growth factors, stem cells, and cytokines to stimulate tissue regeneration and accelerate the healing process. Biological skin substitutes, leveraging tissue engineering and 3D printing technologies, are providing better alternatives to traditional grafts, offering improved compatibility and functionality. Topical agents are benefiting from nanotechnology and sustained release formulations, improving their efficacy in infection control and wound healing.

For instance, in January 2023, Kerecis introduced its GraftGuide fish-skin product line, which addresses the difficulties associated with burn healing. GraftGuide Mano is made to adapt to the shape of a hand. Surgeons do not need to customize the graft because the product can easily cover the three-dimensional structure of the hand. This reduces the surgical time and eliminates the need for numerous grafts and bulky fixation.

Dominance of Hospitals

Due to the complex nature of the hospital environment, wound care is mostly used in hospitals as compared to ambulatory surgical centers and burn care centers. Wounds of varying degrees of severity are more common in hospitals because they typically handle a wide variety of medical cases, including complicated surgeries, trauma, and chronic conditions. Hospitals are equipped with a comprehensive infrastructure that facilitates access to a wide range of wound care resources, advanced diagnostic tools, and specialized medical professionals. Hospitals are the main hub for comprehensive wound care management because they are equipped to handle acute cases that may need intensive care and continuous monitoring. This allows medical professionals to address a wide range of wounds, from severe injuries to post-surgical incisions.

North America Dominates the Global Wound Care Biologics Market

North America's dominance in the global wound care biologics market is being driven by various factors. The region has a well-established healthcare infrastructure that readily adopts and integrates advanced medical technologies. In addition, a high prevalence of chronic conditions such as diabetes and vascular diseases, has led to an increased demand for advanced wound care solutions, positioning biologics as a critical component for treatment protocols. The regulatory environment and reimbursement policies in the United States and Canada further facilitate the widespread adoption of innovative wound care biologics.

In October 2023, MTF Biologics announced that the FDA granted an IDE (Investigational Device Exemption) to initiate a clinical study verifying the efficacy and safety of FlexHD Pliable for breast reconstruction based on implants. This is the first IDE approval for a human acellular dermal matrix for breast reconstruction granted by the FDA.

Future Market Scenario (2024-2031F)

Allografts and xenografts are increasingly being used as skin substitutes beyond just dressings, indicating a shift towards more advanced biologic skin substitutes.

Bioengineered skin substitutes are gaining prominence as an alternative approach to treating large skin defects caused by burns or trauma. These substitutes can be classified based on their chemical composition, scaffold material, and skin components.

Incorporating functional moieties into skin substitutes is a growing trend. For instance, antimicrobials and wound healing agents are being integrated into bioengineered smart skin substitutes. These functionalized substitutes aim to enhance wound healing outcomes and prevent infections.

Key Players Landscape and Outlook

The global wound care biologics market is characterized by a competitive landscape with key players driving innovation and market expansion. These market players are investing in R&D to improve product efficacy, patient comfort, and dosage precision. Partnerships and collaborations between medical device and pharmaceutical companies are being formed with the aim of the development of advanced wound care products that can be integrated with smartphones and applications.

For instance, in May 2023, the Acellular dermal matrix, a natural soft tissue reconstruction solution that AlloSource announced to provide long-term structural support, AlloMend Duo ADM was developed to assist surgeons in reconstructing soft tissue defects. A scaffold for cell repopulation and natural host tissue regeneration is provided by the deep reticular dermal allograft, which blends in with the surrounding tissue.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Wound Care Biologics Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2.By Product
- 4.2.1. Biological Skin Substitutes
- 4.2.2. Topical Agents
4.3.By Wound
- 4.3.1. Ulcers
- 4.3.2. Surgical & Traumatic Wounds
- 4.3.3. Burns
4.4.By End-user
- 4.4.1. Hospitals & Clinics
- 4.4.2. Ambulatory Surgical Centers
- 4.4.3. Burn Care Centers & Wound Clinic
4.5.By Region
- 4.5.1.North America
- 4.5.2.Europe
- 4.5.3.Asia-Pacific
- 4.5.4.South America
- 4.5.5.Middle East and Africa
4.6.By Company Market Share (%), 2023

5.Global Wound Care Biologics Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Product
  - 5.1.2.1.Biological Skin Substitutes
  - 5.1.2.2.Topical Agents
- 5.1.3.By Wound
  - 5.1.3.1.Ulcers
  - 5.1.3.2.Surgical & Traumatic Wounds
  - 5.1.3.3.Burns
- 5.1.4.By End-user
  - 5.1.4.1.Hospitals & Clinics
  - 5.1.4.2.Ambulatory Surgical Centers
  - 5.1.4.3.Burn Care Centers & Wound Clinic
- 5.1.5.United States*
  - 5.1.5.1.Market Size & Forecast
  - 5.1.5.1.1.By Value
  - 5.1.5.1.2.By Volume
  - 5.1.5.2.By Product
  - 5.1.5.2.1.Biological Skin Substitutes
  - 5.1.5.2.2.Topical Agents
  - 5.1.5.3.By Wound
  - 5.1.5.3.1.Ulcers
  - 5.1.5.3.2.Surgical & Traumatic Wounds
  - 5.1.5.3.3.Burns
  - 5.1.5.4.By End-user
  - 5.1.5.4.1.Hospitals & Clinics
  - 5.1.5.4.2.Ambulatory Surgical Centers
  - 5.1.5.4.3.Burn Care Centers & Wound Clinic
- 5.1.6.Canada
- 5.1.7.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3.Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4.South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5.Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. U.A.E.
- 5.5.3. South Africa

6.Market Mapping, 2023

6.1.By Product
6.2.By Wound
6.3.By End-user
6.4.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Clinical Trials
9.2.Patent Landscape
9.3.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Smith & Nephew Plc
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.Integra LifeSciences Corporation
13.3.Stryker Corporation
13.4.Organogenesis Inc
13.5.MixMedx Inc
13.6.Kerecis Limited
13.7.Molnlycke Healthcare AB
13.8.Lynch Biologics
13.9.Skye Biologics Holdings LLC
13.10.Marine Polymer Technologies Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

創傷治療用バイオロジクス市場の評価：製品・創傷・エンドユーザー・地域別の機会および予測 (2017-2031年)

Wound Care Biologics Market Assessment, By Product, By Wound, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の創傷治療用バイオロジクス市場の展望

第5章世界の創傷治療用バイオロジクス市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の展望

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Wound Care Biologics Market Outlook, 2017-2031F

5.Global Wound Care Biologics Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

創傷治療用バイオロジクス市場の評価：製品・創傷・エンドユーザー・地域別の機会および予測 (2017-2031年)

Wound Care Biologics Market Assessment, By Product, By Wound, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の創傷治療用バイオロジクス市場の展望

第5章 世界の創傷治療用バイオロジクス市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の展望

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Wound Care Biologics Market Outlook, 2017-2031F

5.Global Wound Care Biologics Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の創傷治療用バイオロジクス市場の展望

第5章世界の創傷治療用バイオロジクス市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の展望

第14章戦略的提言

第15章当社について・免責事項